GREY WOLF THERAPEUTICS

• 72110 - Research and experimental development on biotechnology

Grey Wolf is a UK and Australian-based drug discovery and development company focused on developing novel immuno-oncology agents. The company was founded in 2017 by experienced industry professionals; Tom McCarthy (Executive Chairman; former President and CEO of Spinifex Pharmaceuticals), and Peter Joyce (CEO; former Project Leader at Vertex Pharmaceuticals). ... Grey Wolf was founded by leading scientists, drug developers and investors committed to delivering next generation oncology therapies... Grey Wolf is working with leading academic and commercial drug discovery and development partners to deliver first-in-class clinical candidates against these strongly validated targets. The core team is strengthened by a network of collaborations with experts in immuno-oncology, antigen presentation and drug discovery across world leading academic institutions, including The University of Oxford, Monash University, and University of Southampton.

Also known as: Grey Wolf, GREY WOLF THERAPEUTICS LIMITED

Registration numbers: 10989365 (CH)

Primary location: Abingdon United Kingdom